This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.
Ovarian cancer first diagnosed and treated;
Pathologically confirmed as epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer;
The stage of the disease is II-IV, and surgery will be performed after evaluation;
Age ≥ 18 years old;
Pathologically confirmed as non-epithelial ovarian cancer;
Surgical treatment cannot be performed after evaluation;
Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;
Patients who do not agree to use clinical first-line targeted drugs;
Newly-diagnosed and treated patients with high-grade serous ovarian cancer who will receive PARP inhibitors as first-line maintenance therapy after surgery and traditional chemotherapy.
Cohort
Prospective
Not listed
Progression-free survival
To determine the different prognosis of patients after using the PARP inhibitor for first-line maintenance treatment, at the same time, the plasma will be collected and tested for ctDNA before using the PARP inhibitor, during use and when the disease is progressing.
Overall survival
Objective response rate
To evaluate the general response of patients with ovarian cancer to PARP inhibitors
Click on the lead sponsor to view all of their trials.
